Women's Peptide Stack Guide: BPC-157, GHK-Cu, and Ipamorelin

Most peptide content online is written from a male perspective, with male physiology as the default. This is a significant gap, because women's hormonal environment, body composition, and physiological needs differ in ways that genuinely affect how peptide protocols should be designed and dosed.

This guide covers the peptide stack best suited for most women in 2026 — BPC-157, GHK-Cu, and ipamorelin — along with the specific hormonal considerations, dosing adjustments, and cycling strategies relevant to female biology.

Why This Stack Works Well for Women

The combination of BPC-157, GHK-Cu, and ipamorelin was selected specifically because it addresses the areas where women most commonly seek improvement — tissue healing, skin and connective tissue quality, sleep, body composition, and recovery — without compounds that interact with sex hormone pathways in ways that are poorly characterized in women.

Some peptides commonly used in male-focused stacks (such as high-dose GHRP-2 or CJC-1295 DAC in aggressive protocols) can produce more pronounced cortisol and prolactin elevations in women. Ipamorelin's selectivity — it does not meaningfully raise cortisol or prolactin — makes it the ideal GH secretagogue for a women's stack.

BPC-157 provides tissue repair, gut health support, and anti-inflammatory effects. Women experience higher rates of certain connective tissue injuries (ACL tears, stress fractures, Achilles tendinopathy) due to anatomical and hormonal factors. BPC-157's documented tendon, ligament, and gut healing effects address these vulnerabilities directly.

GHK-Cu is particularly relevant for women because of its skin benefits. Estrogen plays a major role in maintaining skin collagen and elasticity, and its decline around perimenopause accelerates skin aging significantly. GHK-Cu directly stimulates collagen synthesis, elastin production, and dermal remodeling — providing a targeted intervention for the most visible signs of female aging.

Ipamorelin addresses the somatopause (age-related GH decline) that affects both sexes, but in women it intersects with the hormonal changes of perimenopause and menopause in ways that are particularly impactful. Declining GH output contributes to the increase in visceral fat, reduction in lean mass, and worsening sleep quality that many women experience in their 40s and beyond. Ipamorelin safely restores pulsatile GH signaling without requiring exogenous hormones.

Dosing for Women: Key Adjustments

Women generally respond to lower peptide doses than men due to differences in body composition, receptor sensitivity, and hormonal milieu. Starting at the lower end of established dose ranges and titrating upward based on response is strongly recommended.

BPC-157

• Starting dose: 200–250 mcg per day
• Effective range for most women: 200–400 mcg per day
• Route: Subcutaneous injection (systemic) or oral/sublingual (gut-specific)
• Frequency: Daily, 5 days on, 2 days off
• Cycle: 8–12 weeks on, 4 weeks off

GHK-Cu

• Subcutaneous injection: 1 mg per day (women may achieve equivalent effects at 1 mg versus the 1–2 mg often used in male protocols)
• Topical: Apply 1–3% GHK-Cu serum to face, neck, and décolletage morning and evening
• Subcutaneous cycle: 8–12 weeks on, 4 weeks off
• Topical: Can be used continuously without cycling

Ipamorelin

• Starting dose: 150–200 mcg per day (slightly lower than typical male starting doses)
• Effective range: 150–250 mcg per day
• Timing: Before bed, fasted (2+ hours post-meal)
• Frequency: 5 nights per week (Monday–Friday is a common approach)
• Cycle: 12–16 weeks on, 4–6 weeks off

Hormonal Considerations for Women

Menstrual cycle timing: Some women find that their response to peptides varies across the menstrual cycle. GH secretion is naturally higher in the follicular phase (days 1–14) due to estrogen's stimulating effect on the GH axis. Ipamorelin may produce more pronounced effects during the follicular phase. This is not a reason to dose differently, but understanding this variability helps interpret subjective experiences during the cycle.

Perimenopause and menopause: The peri-menopausal transition brings declining estrogen and progesterone alongside already-declining GH output. Ipamorelin becomes more valuable in this context as a tool to maintain GH secretion that is no longer supported by estrogen signaling. Women in perimenopause often report particularly strong responses to ipamorelin, with sleep quality improvements being especially pronounced.

Thyroid considerations: Women are disproportionately affected by thyroid dysfunction (Hashimoto's thyroiditis, hypothyroidism), which can blunt GH response and reduce the effectiveness of GH secretagogues. Optimize thyroid function before or while running ipamorelin. Thyroid-supporting supplements and confirming free T3/T4 and TSH are in optimal ranges (not just normal ranges) is worthwhile.

Oral contraceptives: Combined oral contraceptives elevate sex hormone binding globulin (SHBG) and can alter the hormonal environment in ways that affect response to GH-axis peptides. There is no evidence of direct contraindication, but women on OCs may notice blunted responses and should adjust expectations accordingly.

Pregnancy and breastfeeding: None of the peptides in this stack have adequate safety data in pregnancy or lactation. Do not use peptides if pregnant, trying to conceive, or breastfeeding. The growth-stimulating effects of ipamorelin and the tissue-remodeling effects of BPC-157 and GHK-Cu have unknown safety profiles in pregnancy. For supplement guidance during these life stages, see supplements for pregnancy and breastfeeding.

The Full Women's Protocol

A practical week structure for a busy woman:

Monday–Friday evening:

• 9:00 PM: BPC-157 injection (200–250 mcg, subcutaneous)
• 9:15 PM: Ipamorelin injection (150–200 mcg, subcutaneous)
• 9:30 PM: GHK-Cu injection (1 mg, subcutaneous)

Morning routine (daily, no cycling needed for topical):

• Apply GHK-Cu serum to face and neck after cleansing
• Reapply in evening skincare routine

Saturday–Sunday: No injections (natural recovery days)

This 5-days-on, 2-days-off structure reduces injection burden, preserves receptor sensitivity, and aligns the protocol with a natural weekly rhythm. It also means women who travel on weekends are not burdened by injections during those days.

Expected Benefits for Women

Skin: GHK-Cu produces measurable improvements in skin texture, elasticity, and fine line reduction within 6–8 weeks of consistent use. This is arguably the most visible and well-documented peptide benefit for women. The combination of topical and subcutaneous GHK-Cu produces stronger results than either route alone.

Body composition: Ipamorelin's GH-stimulating effects support lean mass maintenance and modest fat loss, particularly visceral fat. These effects are most pronounced in women over 35, where declining GH output is contributing to body composition changes. Do not expect dramatic fat loss — this stack is not a fat burner. For a more aggressive body recomposition focus, see our fat loss and muscle gain peptide stack.

Recovery: BPC-157 reduces recovery time from training and accelerates healing of the minor connective tissue injuries that accumulate with active lifestyles. Women in high-impact sports (running, CrossFit, weightlifting) often notice the most dramatic benefits here.

Gut health: BPC-157's gut-protective and gut-healing effects are particularly relevant for women, who have higher rates of IBS, IBD, and general gut sensitivities. Many women report significant improvements in digestive symptoms within the first 2–4 weeks of BPC-157 use.

Sleep and recovery: Ipamorelin's pre-sleep dosing improves deep sleep quality, which cascades into better hormonal balance, mood stability, and daytime energy. This effect is often one of the first benefits women notice and one of the most consistently reported across the community.

Monitoring and Safety

Track the following at baseline and 6–8 weeks into the cycle:

• IGF-1 (confirms ipamorelin is producing GH effect)
• Fasting glucose and insulin (monitor for any GH-driven insulin resistance)
• Thyroid panel (free T3, free T4, TSH)
• Full hormone panel (estradiol, progesterone, testosterone, SHBG) if in perimenopause

See tracking bloodwork for supplements for a comprehensive guide to interpreting these values.

Frequently Asked Questions

Q: Will ipamorelin affect my estrogen or progesterone levels? Ipamorelin does not directly affect sex steroid production or metabolism. It works specifically on the GH axis through the ghrelin receptor. There is no evidence of estrogen or progesterone changes from ipamorelin use in research literature. However, because GH influences IGF-1, which has downstream effects on multiple hormonal systems, a complete hormone panel before and after a cycle is reasonable precaution.

Q: Are there peptides women should avoid? Peptides with the most concerning profiles for women are those that directly affect sex hormone production or have significant prolactin effects. GHRP-2, at high doses, can raise prolactin more than ipamorelin. Melanotan II affects sexual function and pigmentation through pathways poorly characterized in women. PT-141 (bremelanotide) is actually approved for female hypoactive sexual desire disorder, making it an option rather than a concern. For most women, avoiding aggressive GHRH combinations and staying with ipamorelin as the GH secretagogue is the conservative approach.

Q: At what age should women start a peptide stack? There is no single correct answer. Women in their 20s with specific injury recovery needs may benefit from BPC-157. Women in their 30s dealing with early body composition changes or skin aging may begin the full stack. Women in perimenopause or post-menopause are typically the most responsive to the GH axis support from ipamorelin. A starting point guided by specific goals rather than age is most appropriate.

Q: Can I use this stack while on hormone replacement therapy (HRT)? The combination of HRT and peptides is increasingly common among women in the longevity medicine space. There are no known contraindications between this peptide stack and standard HRT (estradiol + progesterone). The two approaches address different biological pathways and can be complementary. Discuss with your prescribing physician to ensure monitoring is comprehensive.

Q: How does GHK-Cu compare to collagen supplements for skin? They work through different mechanisms. Collagen supplements provide amino acid building blocks for collagen synthesis. GHK-Cu directly signals cells to produce more collagen and also stimulates elastin, glycosaminoglycans, and remodeling enzymes that give skin its structure. GHK-Cu has more direct evidence for fine line reduction and skin thickness improvement. The two approaches are complementary — many women use both for synergistic skin benefits. For context on collagen supplementation, see our guide on collagen versus protein powder.